The effects of iloprost and beta3 receptor agonist on TRPA1 and TRPC1 immunreactivity in an experimental lower extremty ischemia-reperfusion injury model

Background/aim: In this study, we aimed to investigate the effects of antioxidant iloprost (ILO) and ß3 adrenergic receptor agonist (BRL) on transient receptor potential ankyrin 1 (TRPA1) and transient receptor potential canonical 1 (TRPC1) ion channels on an experimental ischemia and reperfusion injury model in 30 male Wistar albino rats aged 8–10 weeks. Materials and methods: Wistar Albino rats aged were divided into 5 equal groups. Group I Sham operation, Group II IR (ischemiareperfusion) procedure, Group III IR + intravenous ILO administration, Group IV IR + intraperitoneal BRL administration, and Group V IR + intravenous ILO + intraperitoneal BRL administration group. Two ng/kg/min ILO intravenous infusion was applied to the ILO group. A single dose of 5 mcg/kg BRL intraperitoneal was applied to BRL group. TOS (total oxidant status), TRPA1, and TRPC1 levels were measured with ELISA (enzyme linked immunosorbent assay) in serum, immunohistochemical staining in musculus quadriceps femoris tissue. Results: Compared with the sham group, the IR group had a statistically significant increase in serum levels of TOS (p = 0.004), TRPA1 (p = 0.002), and TRPC1 (p = 0.008) along with TRPA1- and TRPC1-immunoreactivity (p = 0.005, each) in the tissue. When compared with the IR group in terms of serum levels of TRPA1 and tissue TRPA1-immunoreactivity, although there was no statistically significant difference in the IR+Ilo (p = 0.257 and p = 0.429, respectively), IR+Brl (p = 0.024 and p = 0.177, respectively), and IR+Ilo+Brl (p = 0.024 and p = 0.329, respectively) groups, serum levels of TOS and TRPC1 along with tissue TRPC1-immunoreactivity were statistically significantly reduced in the IR+Ilo (p = 0.002, p = 0.008, and p = 0.004, respectively), IR+Brl (p = 0.004, p = 0.008, and p = 0.004, respectively), and IR+Ilo+Brl groups (p = 0.002, p = 0.008, and p = 0.004, respectively). Conclusion: In IR group serum TOS, TRPA1 and TRPC1 levels ,and tissue TRPA1 and TRPC1 immunoreactivity were statistically significant increase when compared to the sham group. In IR+ILO, IR+BRL and IR+ILO+BRL groups serum TRPA1 and tissue TRPA1 immunoreactivity did not change when compared to IR group. Serum TOS and TRPC1 levels, tissue TRPC1 immunoreactivty were statistically significant decreased when compared to IR group. More detailed and expanded population studies are needed to discuss our results.Key words: Rat, iloprost, BRL, TRP, ischemia, reperfusion

PDF

___

1. Gökalp G, Eygi B, Kiray M, Açıkgöz B, Berksoy E et al. How important is the damage to the liver after lower limb ischemiareperfusion? An experimental study in a rat model. Turkish Journal of Thoracic and Cardiovascular Surgery 2020; 28 (1): 127-133. doi: 10.5606/tgkdc.dergisi.2020.18631
2. Calvani M, Subbiani A, Vignoli M, Favre C. Spotlight on ROS and ß3-adrenoreceptors fighting in cancer cells. Oxidative Medicine and Cellular Longevity 2019; 2019. doi: 10.1155/2019/6346529
3. Bagis Z, Ozeren M, Buyukakilli B, Balli E, Yaman S et al. Effect of iloprost on contractile impairment and mitochondrial degeneration in ischemia-reperfusion of skeletal muscle. Physiology International 2018; 105 (1): 61-75. doi: 10.1556/2060.105.2018.1.5
4. Avci T, Erer D, Kucuk A, Oztürk Y, Tosun M et al. The effects of iloprost on ischemia-reperfusion injury in skeletal muscles in a rodent model. Journal of Surgical Research 2014; 187 (1): 162- 168. doi: 10.1016/j.jss.2013.09.031
5. Salie R, Alsalhin AKH, Marais E, Lochner A. Cardioprotective effects of beta3-adrenergic receptor (ß3-AR) pre-, per-, and post-treatment in ischemia-reperfusion. Cardiovascular Drugs and Therapy 2019; 33 (2): 163-177. doi: 10.1007/s10557-019- 06861-5
6. Samanta A, Hughes TET, Moiseenkova-Bell VY. Transient receptor potential (TRP) channels. Subcellular Biochemistry Springer New York; 2018; 87: 141-165. doi: 10.1007/978-981- 10-7757-9_6
7. Dietrich A, Fahlbusch M, Gudermann T. Classical transient receptor potential 1 (TRPC1): channel or channel regulator? Cells 2014; 3 (4): 939-962. doi: 10.3390/cells3040939
8. Chen X, Sooch G, Demaree IS, White FA, Obukhov AG. Transient receptor potential canonical (TRPC) channels: then and now. Cells 2020; 9 (9): 1983. doi:10.3390/cells9091983
9. Jaquemar D, Schenker T, Trueb B. An Ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts. Journal of Biological Chemistry 1999; 274 (11): 7325-7333. doi: 10.1074/ jbc.274.11.7325
10. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003; 112 (6): 819-829. doi: 10.1016/s0092-8674(03)00158-2
11. Zygmunt PM, Högesättt ED. TRPA1. Handbook of Experimental Pharmacology 2014; 222: 583-630. doi: 10.1007/978-3-642-54215-2_23
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 2005; 38: 1103- 1111. doi: 410.1016/j.clinbiochem.2005.08.008
13. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. The Journal of Neuroscience 2008; 28 (10): 2485-2494. doi: 10.1523/jneurosci.5369-07.2008
14. Salie R, Alsalhin AKH, Marais E, Lochner A. Cardioprotective effects of Beta3-adrenergic receptor (ß3-AR) pre-, per-, and post-treatment in ischemia-reperfusion. Cardiovascular Drugs and Therapy 2019; 33 (2): 163-177. doi: 10.1007/s10557-019- 06861-5
15. Lu Y, Piplani H, McAllister SL, Hurt CM, Gross ER. Transient receptor potential ankyrin 1 activation within the cardiac myocyte limits ischemia-reperfusion injury in rodents. Anesthesiology 2016 1; 125 (6): 1171-1180. doi: 10.1097/ aln.0000000000001377
16. Conklin DJ, Guo Y, Nystoriak MA, Jagatheesan G, Obal D et al. TRPA1 channel contributes to myocardial ischemiareperfusion injury. American Journal of Physiology Heart and Circulatory Physiology 2019; 316 (4): 889-899. doi: 10.1152/ ajpheart.00106.2018
17. Gu X, Nan Y, Pang X, Zhang W, Zhang J et al. Products of oxidative stress and transient receptor potential ankyrin A1 expression in the brainstem after lung ischemia– reperfusion injury. Pulmonary Circulation 2019; 9 (3). doi: 10.1177/2045894019865169
18. Jang Y, Kim M, Hwang SW. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. Journal of Neuroinflammation 2020; 17 (1): 1-27. doi: 10.1186/s12974-020-1703-1
19. So K, Tei Y, Zhao M, Miyake T, Hiyama H et al. Hypoxiainduced sensitisation of TRPA1 in painful dysesthesia evoked by transient hindlimb ischemia/reperfusion in mice. Scientific Reports 2016; 6: 1-12. doi: 10.1038/srep23261
20. Sasaki A, Mizoguchi S, Kagaya K, Shiro M, Sakai A et al. A mouse model of peripheral postischemic dysesthesia: involvement of reperfusion-induced oxidative stress and TRPA1 channel. The Journal of Pharmacology and Experimental Therapeutics 2014; 351 (3): 568-575. doi: 10.1124/jpet.114.217570
21. Xu N, Meng H, Liu T, Feng Y, Qi Y et al. TRPC1 Deficiency exacerbates cerebral ischemia/reperfusion-induced neurological injury by potentiating nox4-derived reactive oxygen species generation. Cellular Physiology Biochemistry 2018; 51 (4): 1723-1738. doi: 10.1159/000495676
22. Choi JH, Jeong SY, Oh MR, Allen PD, Lee EH. TRPCs: influential mediators in skeletal muscle. Cells 2020; 9 (4): 850. doi: 10.3390/cells9040850
23. Gervásio OL, Whitehead NP, Yeung EW, Phillips WD, Allen DG. TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy. Journal of Cell Science 2008; 121 (13): 2246-2255. doi: 10.1242/jcs.032003
Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circulation Research 2004; 95 (5): 496-505. doi: 10.1161/01.res.0000138952.16382.ad
25. Xia Y, Yang X-R, Fu Z, Paudel O, Abramowitz J et al. classical transient receptor potential 1 and 6 contribute to hypoxic pulmonary hypertension through differential regulation of pulmonary vascular functions. Hypertension 2014; 63 (1): 173- 180. doi: 10.1161/hypertensionaha.113.01902
26. Lu W, Ran P, Zhang D, Peng G, Li B et al. Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. American Journal of Physiology cell Physiology 2010; 298 (1): 114-123. doi: 10.1152/ajpcell.00629.2008
27. Wang J, Jiang Q, Wan L, Yang K, Zhang Y et al. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. American Journal of Respiratory Cell and Molecular Biology 2013; 48 (1): 125-134. doi: 10.1165/rcmb.2012-0071oc
28. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth H-J. Inhaled iloprost for the control of pulmonary hypertension. Vascular Health and Risk Management 2009; 5 (1): 465-474. doi: 10.2147/vhrm.s3223